imatinib mesylate has been researched along with Thrombocythemia, Essential in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Ebisawa, K; Kurokawa, M; Masamoto, Y; Yagi, K | 1 |
| Abecasis, M; Du, Z; Hu, R; Liu, C; Wang, C | 1 |
| Xicoy, B; Zamora, L | 1 |
| Han, SA; Lee, YJ; Moon, JH; Seo, JW; Seo, SK; Shin, HC; Sohn, SK | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A | 1 |
| Albajar, M; Delgado, MD; Gómez-Casares, MT; Gutierrez, P; León, J; Richard, C; Rosa-Garrido, M; Steegmann, JL | 1 |
| Hoffman, R; Kiladjian, JJ; Mesa, RA | 1 |
| Popat, U; Rice, L | 1 |
| Campbell, PJ; Curtin, NJ; Green, AR | 1 |
| Cabello, P; Cesar, JM; Ferro, T; Navarro, JL | 1 |
3 review(s) available for imatinib mesylate and Thrombocythemia, Essential
| Article | Year |
|---|---|
Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review.
Topics: Antineoplastic Agents; Calreticulin; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein-Tyrosine Kinases; Thrombocythemia, Essential | 2020 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential | 2011 |
8 other study(ies) available for imatinib mesylate and Thrombocythemia, Essential
| Article | Year |
|---|---|
A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.
Topics: Humans; Imatinib Mesylate; Janus Kinase 2; Mutation; Polycythemia Vera; Thrombocythemia, Essential | 2022 |
Current treatment of myeloproliferative neoplasias: three scenarios.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Niacinamide; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Thrombocythemia, Essential; Time Factors; Withholding Treatment | 2020 |
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thrombocythemia, Essential | 2013 |
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2015 |
PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Middle Aged; Myeloid Cells; Piperazines; Polycythemia Vera; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Thrombocythemia, Essential; Trans-Activators; Transfection; Treatment Outcome | 2008 |
Every case of essential thrombocythemia should be tested for the Philadelphia chromosome.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chronic Disease; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential | 2005 |
The Philadelphia translocation and pre-existing myeloproliferative disorders.
Topics: Antineoplastic Agents; Benzamides; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic | 2005 |
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome | 2006 |